2171.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 11:08):

Stats
Dzisiejszy wolumen	2.01M
Średni wolumen	1.27M
Kapitalizacja rynkowa	3.42B
EPS	HKD0 ( 2024-03-26 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-4.01
ATR14	HKD0.0330 (0.57%)

Wolumen Korelacja

Długi: 0.26 (neutral)

Krótki: 0.97 (very strong)

Signal:(58.557) Expect same movement, but be aware

CARsgen Therapeutics Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CARsgen Therapeutics Korelacja - Waluta/Towar

-0.56
( weak negative )

-0.71
( moderate negative )

0.00
( neutral )

-0.72
( moderate negative )

-0.40
( neutral )

0.50
( neutral )

CARsgen Therapeutics Finanse

Annual	2023
Przychody:	HKD0
Zysk brutto:	HKD0 (0.00 %)
EPS:	HKD-1.340

FY	2023
Przychody:	HKD0
Zysk brutto:	HKD0 (0.00 %)
EPS:	HKD-1.340

FY	2022
Przychody:	HKD0
Zysk brutto:	HKD0 (0.00 %)
EPS:	HKD-1.620

FY	2021
Przychody:	HKD25.81M
Zysk brutto:	HKD25.81M (100.00 %)
EPS:	HKD-8.36

Financial Reports:

No articles found.

CARsgen Therapeutics

CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.